Abstract 2760
Background
TMB is an emerging biomarker for immune-therapy including metastasized UBC. The evaluation of reliable methods to determine the TMB value is a prerequisite for successful application of IO therapies.
Methods
TMB was assessed in genomic DNA from 39 muscle-invasive UBC by whole genome sequencing (GPS Cancer©, NantHealth). In 45 cases sequencing with the TruSight Oncology 500, (TSO500, Illumina) was performed. Immune cell (IC) infiltrates were analyzed by CD3, CD8, CD56, PD-1 and CD68 immunohistochemistry. PD-L1 status was evaluated by the SP263 assay (Ventana). Intrinsic subtypes (MDACC-approach) were assessed via a Nanostring-assay. Immune phenotypes were assessed by (I) spatial distribution of IC and (II) a T-cell inflammation related gene expression signature consisting of 29 genes (Nanostring). Results were validated in the TCGA MIBC cohort.
Results
Correlation between TSO500 and WGS revealed high concordance (spearman-correlation: r = 0.68, p < 0.0001). Overall percentage agreement was 76.9% for a cut-off of 10 mut/mb and 84.6% for 15 mut/mb. We found no significant association of high TMB at different cut-offs (10 mut/mb, 15 mut/mb) with inflammation status and different immune cell populations in both cohorts. TMB was not associated with intrinsic subtypes. Spatially distributed IC phenotypes or PD-L1 status was not associated with TMB. Hierarchical clustering of all factors revealed four distinct subgroups: Cluster A Inflamed, PD-L1 “high”, TMB high (n = 5); Cluster B Inflamed, PD-L1 “high”, TMB low-intermediate (n = 14); Cluster C: Uninflamed, PD-L1 “low”, TMB intermediate-high (n = 14); Cluster D Uninflamed, PD-L1 “low”, TMB low (n = 12).
Conclusions
This study provides insights into the reliability of a NGS panel for the prediction of TMB in MIBC which shows comparable performance to WGS. High TMB seems to be a characteristic of MIBC which occurs regardless of PD-L1 and inflammation status. TMB could possibly identify additional patients who do not fulfill the PD-L1 assessment based criteria for checkpoint inhibition.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Illumina, California, United States of America NantHealth, Culver City, California, United States of America.
Disclosure
M. Eckstein: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy: Janssen-Cilag. All other authors have declared no conflicts of interest.
Resources from the same session
2036 - Salivary metabolomics for colorectal cancer detection
Presenter: Hiroshi Kuwabara
Session: Poster Display session 3
Resources:
Abstract
1868 - Evaluation and diagnostic potential of plasma biomarkers in bladder cancer
Presenter: Veronika Voronova
Session: Poster Display session 3
Resources:
Abstract
3655 - Liquid biopsy assays using combined circulating tumor cells and circulating tumor DNA in the same patients for the diagnosis of primary lung cancer
Presenter: Yongjoon Suh
Session: Poster Display session 3
Resources:
Abstract
3685 - Peripheral Cytotoxic T Cell Correlates with Tumor Mutational Burden and is Predictive for Progression Free Survival in Advanced Breast Cancer
Presenter: Xiao-ran Liu
Session: Poster Display session 3
Resources:
Abstract
1050 - Splenic Metabolic Activity as Biomarker in Cervical Cancer
Presenter: Emiel De Jaeghere
Session: Poster Display session 3
Resources:
Abstract
1413 - Identification of distinct subtypes revealing prognostic and therapeutic relevance in diffuse type gastric cancer
Presenter: Seon-Kyu Kim
Session: Poster Display session 3
Resources:
Abstract
2140 - Recurrence risk evaluation in stage IB/IIA gastric cancer with TP53 codon 72 polymorphisms
Presenter: Satoshi Nishizuka
Session: Poster Display session 3
Resources:
Abstract
1573 - Identification and validation of a prognostic 4 genes signature for hepatocellular carcinoma: integrated ceRNA network analysis
Presenter: Yongcong Yan
Session: Poster Display session 3
Resources:
Abstract
1196 - Plasma KIM-1 is associated with clinical outcomes after resection for localized renal cell carcinoma: A trial of the ECOG-ACRIN Research Group (E2805)
Presenter: Wenxin Xu
Session: Poster Display session 3
Resources:
Abstract
2657 - Prognostic immunoprofiling of muscle invasive bladder cancer (MIBC) patients in a multicentre setting
Presenter: Katharina Nekolla
Session: Poster Display session 3
Resources:
Abstract